Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounding with Beta-1, 3-D-Glucan

Author(s):  Keller Ted

Issue:  Sep/Oct 2000 - Compounding for Immune System Disorders
View All Articles in Issue

Page(s):  342

Compounding with Beta-1, 3-D-Glucan Page 1

Download in electronic PDF format for $75

Abstract:  Beta-1,3-D-glucan, a homopolymer of glucose, is a brown powder consisting of beta-1,3-linked glucopyranose polymers, which are insoluble molecules in all solvents. In this article, various therapeutic applications of beta-1,3-D-glucan and its effect on the role of the macrophage in immune system functioning are presented. The author focuses on infectious diseases; allergy and breathing disorders; neoplastic disease and the side effects of treatment; diabetes, hypertension, cholesterol and liver disease; autoimmune disorders; dermatologic applications and additional benefits of treatment. She also provides four very brief case reports. She concludes that beta-1,3-D-glucan is a powerful adjunct to the treatment of several disorders and should be included in every compounding practice. Its disadvantage is that, if treatment fails, the expense of therapy has been wasted; however, therapeutic failures are infrequent.

Related Keywords: glucan, beta-1,3-D, infectious disease

Related Categories: NUTRITION AND NUTRICEUTICALS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounding with Beta-1, 3-D-Glucan
Keller Ted
Sep/Oct 2000
Pg. 342

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Treating Canine Hepatic Disease
Davidson Gigi S
May/Jun 2003
Pg. 188-191

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A
, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Jul/Aug 2016
Pg. 328-332

Compounding for Treatment of Equine Infectious Diseases: An Overview
Bramwell Bethany L
Nov/Dec 2011
Pg. 450-457

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Addendum to Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine A New Therapeutic Modality
Mar/Apr 2024
Pg. 129

Esmolol Hydrochloride 10-mg/mL Injection
Allen Loyd V Jr
Sep/Oct 2012
Pg. 420

Equine Cushing's Disease: A Clinical Update
Bliss George
Sep/Oct 2007
Pg. 384-388

Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
Harrington Amy
, Williams LaVonn
Jul/Aug 2022
Pg. 293-296

Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Nov/Dec 2021
Pg. 503

Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
May/Jun 2004
Pg. 206-209

Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
May/Jun 2003
Pg. 170-174

The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene
, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, LlambĂ­ Francesc
Jan/Feb 2014
Pg. 6-12

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Return to Top